TG4010: a vaccine with a therapeutic role in cancer

被引：14
作者：
Arriola, Edurne [1 ,2 ]
Ottensmeier, Christian [1 ,2 ]
机构：
[1] Univ Southampton, Fac Med, Southampton NIHR Expt Canc Med Ctr, Tremona Rd, Southampton SO16 6YD, Hants, England
[2] Univ Hosp Southampton NHS Fdn Trust, Tremona Rd, Southampton SO16 6YD, Hants, England
来源：
IMMUNOTHERAPY | 2016年 / 8卷 / 05期
关键词：
MUC1; MVA-MUC1-IL-2; non-small-cell lung cancer; TG4010; TIME trial; TrPAL; vaccine; CELL LUNG-CANCER; MAJOR HISTOCOMPATIBILITY COMPLEX; MUC1; EXPRESSION; MONOCLONAL-ANTIBODY; CORE PROTEIN; IMMUNOTHERAPY; STAGE; ANTIGEN; MUCINS; CARCINOMA;
D O I：
10.2217/imt-2016-0015
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
One of the strategies to enhance immune response against tumors has been the use of vaccines against tumor-associated antigens (TAAs). MUC1 is a TAA that is overexpressed in many malignancies being linked to worse prognosis. Moreover, tumor MUC1 is hypoglycosylated revealing new epitopes that are antigenic and potential T-cell targets. TG4010 is a recombinant viral vaccine targeting MUC1, also encoding for IL-2. TG4010 has been tested in Phase I-II trials demonstrating a consistent safety profile with mild local reactions as main side effect. These studies have confirmed immune responses to the vaccine product. Clinical efficacy has been observed mainly in patients with non-small-cell lung cancer in combination with chemotherapy. Peripheral activated NK cells are currently being validated as biomarkers of response.
引用
收藏
页码：511 / 519
页数：9
相关论文
共 65 条
[1]   MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines [J].
Acres, B ;
Apostolopoulos, V ;
Balloul, JM ;
Wreschner, D ;
Xing, PX ;
Ali-Hadji, D ;
Bizouarne, N ;
Kieny, MP ;
McKenzie, IFC .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2000, 48 (10) :588-594
[2]   Targeted Immunotherapy Designed to Treat MUC1-Expressing Solid Tumour [J].
Acres, Bruce ;
Lacoste, Gisele ;
Limacher, Jean-Marc .
CANCER VACCINES, 2017, 405 :79-97
[3]  
Baldus SE, 1998, INT J CANCER, V79, P133, DOI 10.1002/(SICI)1097-0215(19980417)79:2<133::AID-IJC6>3.0.CO
[4]  
2-U
[5]   SPECIFIC, MAJOR HISTOCOMPATIBILITY COMPLEX - UNRESTRICTED RECOGNITION OF TUMOR-ASSOCIATED MUCINS BY HUMAN CYTO-TOXIC T-CELLS [J].
BARND, DL ;
LAN, MS ;
METZGAR, RS ;
FINN, OJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (18) :7159-7163
[6]   CD56brightCD16+ NK Cells: A Functional Intermediate Stage of NK Cell Differentiation [J].
Beziat, Vivien ;
Duffy, Darragh ;
Stephanie Nguyen Quoc ;
Le Garff-Tavernier, Magali ;
Decocq, Julie ;
Combadiere, Behazine ;
Debre, Patrice ;
Vieillard, Vincent .
JOURNAL OF IMMUNOLOGY, 2011, 186 (12) :6753-6761
[7]   Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].
Borghaei, H. ;
Paz-Ares, L. ;
Horn, L. ;
Spigel, D. R. ;
Steins, M. ;
Ready, N. E. ;
Chow, L. Q. ;
Vokes, E. E. ;
Felip, E. ;
Holgado, E. ;
Barlesi, F. ;
Kohlhaeufl, M. ;
Arrieta, O. ;
Burgio, M. A. ;
Fayette, J. ;
Lena, H. ;
Poddubskaya, E. ;
Gerber, D. E. ;
Gettinger, S. N. ;
Rudin, C. M. ;
Rizvi, N. ;
Crino, L. ;
Blumenschein, G. R. ;
Antonia, S. J. ;
Dorange, C. ;
Harbison, C. T. ;
Finckenstein, F. Graf ;
Brahmer, J. R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639
[8]   Overexpressed oncogenic tumor-self antigens New vaccine targets [J].
Bright, Robert K. ;
Bright, Jennifer D. ;
Byrne, Jennifer A. .
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (11) :3297-3305
[9]   Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies [J].
Brossart, P ;
Heinrich, KS ;
Stuhler, G ;
Behnke, L ;
Reichardt, VL ;
Stevanovic, S ;
Muhm, A ;
Rammensee, HG ;
Kanz, L ;
Brugger, W .
BLOOD, 1999, 93 (12) :4309-4317
[10]  
BURCHELL J, 1987, CANCER RES, V47, P5476
1234567